FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801335938> ?p ?o ?g. }

• W2801335938 abstract "617 Background: There is limited, often conflicting evidence about AE timing, severity or associations with outcomes with the use of cytotoxic agents in cancer treatment. We investigated the impact on overall survival (OS) and progression-free survival (PFS) of selected common AEs (neutropenia, diarrhea, nausea, vomiting, neuropathy) occurring in patients receiving first line oxaliplatin (Oxa)- and/or irinotecan(Iri)-based regimens for mCRC. Methods: The CTCAE grading scores of at least one AE of interest were available on 9812 pts treated with chemotherapy alone (median age 63; 62.4% male, 50.1% ECOG PS 0) from 17 1 st -line randomized trials. Patients who also received biologics were excluded in the primary analyses. AEs occurring during the first 6 weeks of treatment and entire treatment were analyzed by stratified multivariable Cox models in relationship to OS/PFS. 55.7% pts received Oxa- regimens, 35.7% Iri-regimens, and 8.6% combined Oxa- and Iri-regimens. Results: Within the first 6 weeks of treatment, G3+ neutropenia (HR adj = 1.3, 95% CI, 1.06-1.59, p adj 0.01), diarrhea (HR adj = 1.48, 95% CI, 1.23-1.79, p adj < .0001), nausea (HR adj = 1.53, 95% CI, 1.17-1.99, p adj 0.002) and vomiting (HR adj = 1.56, 95% CI, 1.18-2.07, p adj 0.002) were associated with significantly worse OS for Iri-regimens, but only G3+ nausea predicted for worse OS for Oxa- regimens (HR adj = 1.61, 95% CI, 1.18-2.21, p adj 0.003). For AEs experienced at any time, G3+ neutropenia and neuropathy were significantly associated with longer PFS and OS for Oxa-regimens, while G3+ vomiting and nausea were associated with worse OS for both Oxa- and Iri-based regimens. Sensitivity analysis showed largely concordant results by including pts who also received biologics. Conclusions: The association between more severe selected AEs and outcome varies between AEs and is influenced by timing of the occurrence. More severe selected AEs occurring early in treatment are associated with worse outcomes. In contrast, for AEs occurring at any time, G3+ neutropenia and neuropathy predicted for longer PFS and/or OS in Oxa-treated pts." @default.
• W2801335938 created "2018-05-17" @default.
• W2801335938 creator A5007291981 @default.
• W2801335938 creator A5008173055 @default.
• W2801335938 creator A5012034272 @default.
• W2801335938 creator A5013525685 @default.
• W2801335938 creator A5016667774 @default.
• W2801335938 creator A5028938155 @default.
• W2801335938 creator A5032414015 @default.
• W2801335938 creator A5037120205 @default.
• W2801335938 creator A5042517605 @default.
• W2801335938 creator A5045618241 @default.
• W2801335938 creator A5046311492 @default.
• W2801335938 creator A5049291606 @default.
• W2801335938 creator A5049314303 @default.
• W2801335938 creator A5054670872 @default.
• W2801335938 creator A5058562981 @default.
• W2801335938 creator A5060867913 @default.
• W2801335938 creator A5078383767 @default.
• W2801335938 creator A5079686267 @default.
• W2801335938 creator A5088658336 @default.
• W2801335938 creator A5090645179 @default.
• W2801335938 date "2018-02-01" @default.
• W2801335938 modified "2023-09-22" @default.
• W2801335938 title "Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database." @default.
• W2801335938 doi "https://doi.org/10.1200/jco.2018.36.4_suppl.617" @default.
• W2801335938 hasPublicationYear "2018" @default.
• W2801335938 type Work @default.
• W2801335938 sameAs 2801335938 @default.
• W2801335938 citedByCount "0" @default.
• W2801335938 crossrefType "journal-article" @default.
• W2801335938 hasAuthorship W2801335938A5007291981 @default.
• W2801335938 hasAuthorship W2801335938A5008173055 @default.
• W2801335938 hasAuthorship W2801335938A5012034272 @default.
• W2801335938 hasAuthorship W2801335938A5013525685 @default.
• W2801335938 hasAuthorship W2801335938A5016667774 @default.
• W2801335938 hasAuthorship W2801335938A5028938155 @default.
• W2801335938 hasAuthorship W2801335938A5032414015 @default.
• W2801335938 hasAuthorship W2801335938A5037120205 @default.
• W2801335938 hasAuthorship W2801335938A5042517605 @default.
• W2801335938 hasAuthorship W2801335938A5045618241 @default.
• W2801335938 hasAuthorship W2801335938A5046311492 @default.
• W2801335938 hasAuthorship W2801335938A5049291606 @default.
• W2801335938 hasAuthorship W2801335938A5049314303 @default.
• W2801335938 hasAuthorship W2801335938A5054670872 @default.
• W2801335938 hasAuthorship W2801335938A5058562981 @default.
• W2801335938 hasAuthorship W2801335938A5060867913 @default.
• W2801335938 hasAuthorship W2801335938A5078383767 @default.
• W2801335938 hasAuthorship W2801335938A5079686267 @default.
• W2801335938 hasAuthorship W2801335938A5088658336 @default.
• W2801335938 hasAuthorship W2801335938A5090645179 @default.
• W2801335938 hasBestOaLocation W28013359382 @default.
• W2801335938 hasConcept C120665830 @default.
• W2801335938 hasConcept C121332964 @default.
• W2801335938 hasConcept C121608353 @default.
• W2801335938 hasConcept C126322002 @default.
• W2801335938 hasConcept C143998085 @default.
• W2801335938 hasConcept C197934379 @default.
• W2801335938 hasConcept C2776694085 @default.
• W2801335938 hasConcept C41008148 @default.
• W2801335938 hasConcept C526805850 @default.
• W2801335938 hasConcept C61511704 @default.
• W2801335938 hasConcept C71924100 @default.
• W2801335938 hasConcept C77088390 @default.
• W2801335938 hasConceptScore W2801335938C120665830 @default.
• W2801335938 hasConceptScore W2801335938C121332964 @default.
• W2801335938 hasConceptScore W2801335938C121608353 @default.
• W2801335938 hasConceptScore W2801335938C126322002 @default.
• W2801335938 hasConceptScore W2801335938C143998085 @default.
• W2801335938 hasConceptScore W2801335938C197934379 @default.
• W2801335938 hasConceptScore W2801335938C2776694085 @default.
• W2801335938 hasConceptScore W2801335938C41008148 @default.
• W2801335938 hasConceptScore W2801335938C526805850 @default.
• W2801335938 hasConceptScore W2801335938C61511704 @default.
• W2801335938 hasConceptScore W2801335938C71924100 @default.
• W2801335938 hasConceptScore W2801335938C77088390 @default.
• W2801335938 hasLocation W28013359381 @default.
• W2801335938 hasLocation W28013359382 @default.
• W2801335938 hasOpenAccess W2801335938 @default.
• W2801335938 hasPrimaryLocation W28013359381 @default.
• W2801335938 hasRelatedWork W126574499 @default.
• W2801335938 hasRelatedWork W1748341720 @default.
• W2801335938 hasRelatedWork W2043647642 @default.
• W2801335938 hasRelatedWork W2240838598 @default.
• W2801335938 hasRelatedWork W2324888499 @default.
• W2801335938 hasRelatedWork W2507923170 @default.
• W2801335938 hasRelatedWork W2519715308 @default.
• W2801335938 hasRelatedWork W2520145764 @default.
• W2801335938 hasRelatedWork W2553755210 @default.
• W2801335938 hasRelatedWork W2580571506 @default.
• W2801335938 hasRelatedWork W2589326985 @default.
• W2801335938 hasRelatedWork W2589723661 @default.
• W2801335938 hasRelatedWork W2599979212 @default.
• W2801335938 hasRelatedWork W2889914827 @default.
• W2801335938 hasRelatedWork W2891043497 @default.
• W2801335938 hasRelatedWork W3031307103 @default.
• W2801335938 hasRelatedWork W3095986263 @default.
• W2801335938 hasRelatedWork W3161802376 @default.
• W2801335938 hasRelatedWork W3166811299 @default.
• W2801335938 hasRelatedWork W2909787771 @default.

• next